2021 (v1)
Publication
No description
Uploaded on: April 14, 2023
C
Last name: CAROTI C
No description
No description
No description
Background. To determine whether a dose-dense regimen improves outcome in early breast cancer patients, we compared outcomes with the same fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapeutic regimen administered every 3 weeks (FEC21) or administered every 2 weeks (FEC14 including support with filgrastim, a granulocyte...